10x Genomics price target lowered to $15 from $18 at Barclays
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
10x, Harvard settle genomics patent dispute with Vizgen during trial
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
10x Genomics sees robust growth across platforms in Q4 2023
CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...
10x Genomics Full Year 2024 Earnings: EPS Misses Expectations
Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY ...
Seattle's Parse Biosciences lands another legal victory in patent dispute
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
10x Genomics: Q4 Earnings Snapshot
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
10x Genomics, Inc.: 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...
10X Genomics stock plunges to 52-week low of $11.89
In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...